Certainly, GLP-1 analogues have the advantage of not affecting blood sugar levels in nondiabetic people and so may represent a potential safe treatment for AD or other neurodegenerative conditions also in non-diabetic patients. This evidence concerns the gene GLP1R and Alzheimer disease.